Exosomes versus peptides: what is actually being applied to the skin

What, exactly, is an exosome

In the specialist literature, “exosome” is just one name within a larger family. The International Society for Extracellular Vesicles (ISEV) defines extracellular vesicles (EVs) as a collective term covering cell-released membranous structures called exosomes, microvesicles, microparticles, ectosomes, oncosomes or apoptotic bodies, among other names¹. Their size and amount make them difficult to obtain as relatively pure preparations and to characterize properly¹.

ISEV itself is cautious about the trendy term. Its 2018 guidelines state that “claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally,” because little is still known about the machinery that sets them apart from other biophysically similar EVs¹. The MISEV2023 update, built with input from expert task forces and more than 1000 researchers, still lists nomenclature, separation of EVs from non-vesicular extracellular particles, characterization and functional studies as hurdles².

That is the biological starting point: what a product label calls “exosomes” is, at best, a mixture of vesicles with complex cargo (proteins, lipids, nucleic acids) that reflects the state of the cell of origin². A broader view of regenerative aesthetics in the US is summarized in Regenerative aesthetics in New York and Beverly Hills.

Where they come from: stem cells, platelets and plants

The most cited commercial sources are three. Mesenchymal stem cells (MSCs), from adipose tissue, umbilical cord or placenta, are the most studied; a group of four scientific societies (SOCRATES, ISEV, ISCT and ISBT) acknowledged discrepancies about their biology, function and potency due to the diversity of MSCs themselves, the various production and separation methods and the lack of standardized quality-assurance assays³. Platelet-rich plasma derivatives are presented as an autologous variant: in a pilot study, 11 women received 3 sessions of exosomes obtained from their own preconditioned PRP²¹. And so-called “plant exosomes” (plant-derived vesicles or exosome-like nanoparticles) sit on the market alongside human- and animal-derived products⁵.

On the latter, a 2026 toxicology review warns that “an edible plant origin should not be considered a surrogate for safety,” especially with high, repeated or non-oral doses, and that plant source, growth conditions, harvest timing, isolation workflow, storage and co-isolated contaminants can alter vesicle composition⁶.

The underlying problem: knowing what is in the vial

For MSC-derived EVs, the scientific societies proposed defining each preparation by quantifiable metrics: cellular origin, presence of lipid-membrane vesicles and physical and biochemical integrity, ideally measured against a well-characterized reference material³. That standard is not yet the norm in aesthetics. An overview of reviews assessed 17 systematic reviews covering 556 primary studies and found a prevalent deficiency in adherence to ISEV standards, notably in source characterization and bioactive constituents, with a pervasive methodological shortfall on AMSTAR-2⁴.

The market reflects the same gap. An analysis of 18 manufacturers and 70 formulations found high transparency in only 18% of them, significant variability in growth-factor concentrations across human-, plant- and animal-derived products, no FDA-approved products and that 27% of the claims analyzed were misleading⁵. For the physician, the practical consequence is that two vials with the same word on the label may not be comparable with each other, or with the product used in the published trial.

What trials show in skin and hair

There are real clinical signals, and they are worth knowing precisely. The largest meta-analysis, published in 2026 in Aesthetic Surgery Journal, included 39 human studies (26 skin, 13 hair): facial wrinkle reduction averaged 20.2% (95% CI, 15.3%–25.2%), other skin outcomes improved by 14.7% to 23.4%, and hair density and thickness improved by 23.6% and 18.0%, respectively⁷. The authors identified 9 ongoing trials and cautioned that heterogeneity and nonstandardized protocols limit generalizability⁷.

Another systematic review of 19 skin-rejuvenation studies found that most were not randomized, that benefits were seen in the short term and that topical application generally had a good safety profile, with individual reports of risks with off-label injectable use⁸. In hair, a pilot randomized trial in 20 men with androgenetic alopecia (Norwood 2–3) compared an exosome-containing plant formulation with saline over 4 sessions; the change in hair count at 16 weeks was greater with the active product (p = 0.006), with no notable adverse effects⁹.

The FDA's position

The agency is unequivocal: “There are currently no FDA-approved exosome products,” and “exosome products intended to treat diseases or conditions in humans require FDA approval”¹⁰. In December 2019, the FDA reported “multiple recent reports of serious adverse events” in Nebraska patients treated with unapproved products marketed as containing exosomes, and noted that exosomes used to treat diseases are regulated as drugs and biological products subject to premarket review¹¹. The regulatory comparison between cell products and peptides is developed in The double standard.

The contrast: a molecule with a sequence

A peptide is a different category of object. GHK, for example, is the tripeptide glycyl-L-histidyl-L-lysine, with formula C14H24N6O4 and molecular weight 340.38 g/mol¹⁴; its copper complex is GHK-Cu. A defined sequence makes it possible to verify identity and quantify purity: for an angiotensin II reference material, three orthogonal methods (tandem mass spectrometry, quantitative NMR and mass balance) agreed on a purity of 691 ± 9 mg/g, and also quantified the trifluoroacetate counter-ion at nearly 25% by mass¹⁵. How to read those data in a batch document is explained in How to read a certificate of analysis.

That chemical definition is what has allowed a regulatory history that exosomes do not yet have: since insulin, more than 80 peptide drugs have reached the market for diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain¹². In 2025 alone, elamipretide became the first disease-specific treatment approved for Barth syndrome¹³.

In skin, signal peptides have controlled trials. In a randomized, double-blind, split-face study in 93 women aged 35 to 55, the palmitoyl pentapeptide pal-KTTKS at 3 ppm was associated with significant improvement in wrinkles and fine lines vs vehicle at 12 weeks¹⁷. With GHK-Cu, the only randomized trial after CO2 laser (13 patients) showed no objective differences in erythema or wrinkles, although satisfaction was higher with the peptide (P = .04)¹⁶; its biology is detailed in GHK-Cu: the mechanism of action, step by step.

Honest limits on both sides

• Exosomes have favorable signals: average improvements of 20.2% in wrinkles and 23.6% in hair density in the meta-analysis⁷, and a randomized hair trial with a significant difference vs placebo⁹. Dismissing them as pure marketing does not fit the data.
• But their evidence carries the identity problem: most studies are not randomized and protocols are not standardized⁷⁸, and source and cargo characterization is deficient in much of the literature⁴.
• Topical peptides are not rich in trials either: a meta-analysis of 19 randomized trials with 1,341 participants found a modest pooled effect on wrinkles (MD = 0.27, p = 0.04), driven mainly by oral polypeptides, and inconsistent effects on elasticity and density, with good tolerability¹⁸.
• And cosmetic peptide studies are methodologically weak: of 15 studies with matrix-stimulating peptides, only 6 used placebo and 5 were double-blind¹⁹.
• Peptide purity must be checked, not assumed: in independent quality control, only 44.0% of research peptides met the requested purity, and one had a structure different from the one declared²⁰. The peptide's advantage is that such a check is possible.

What it means for the practice

The patient who asks about exosomes has usually seen results on social media, where positive sentiment dominates⁵. The most useful answer is not a no, but a question: what source, what isolation method, what characterization and what unit of quantity does the manufacturer declare³⁵. Against that, the physician who works with peptides can offer something concrete: a molecule with a chemical name, sequence and molecular weight, whose identity and purity can be checked batch by batch¹⁴¹⁵. In a specialty where patient trust is the main asset, that traceability matters.